Teprotumumab was effective for chorioretinal folds caused by active thyroid eye disease

Introduction We report a patient with type 1 diabetes in whom teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, produced a marked response in chorioretinal folds thought to be caused by active thyroid eye disease. Case Presentation The patient was a 73-year-old man. Although he improved after three courses of steroid pulse therapy at a previous hospital for active thyroid eye disease, which manifested as eyelid swelling and impaired ocular movement, the disease relapsed, with bilateral chorioretinal folds and decreased visual acuity in the left eye; therefore, teprotumumab was initiated. One week after treatment initiation, the chorioretinal folds in both eyes had resolved, and left-eye visual acuity had improved. Conclusion Although teprotumumab has been reported to be effective for proptosis and binocular diplopia caused by active thyroid eye disease, this case suggests that it may also be effective for active thyroid eye disease complicated by chorioretinal folds.